ASCO 2025: Key Highlights in Advanced Lung Cancer - Medscape In extensive-stage small cell lung cancer, tarlatamab demonstrated superiority over chemotherapy in the DeLLphi-304 trial, with favorable patient-reported outcomes including improved cough and
Is It Worth Adding Chemo to ICI for NSCLC in Older Adults? Immune checkpoint inhibitors (ICI) are a cornerstone of non-small cell lung cancer (NSCLC) treatment, but it’s not clear whether adding chemotherapy to ICI — a common practice with younger
Potential Drivers of LCINS - Medscape An American Cancer Society expert urges clinicians to advocate for action in the healthcare industry to help combat climate change and its effects on lung cancer incidence